Lake Street Maintains Buy on Achieve Life Sciences, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a Buy rating on Achieve Life Sciences (NASDAQ: ACHV) but lowers the price target from $22 to $19.
May 31, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lake Street analyst maintains Buy rating on Achieve Life Sciences (ACHV) but lowers price target from $22 to $19.
The news of Lake Street maintaining a Buy rating on Achieve Life Sciences (ACHV) is positive for the stock. However, the lowering of the price target from $22 to $19 may create some uncertainty among investors. The overall impact on the stock price in the short term is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100